Accelerate Diagnostics (NASDAQ:AXDX) Upgraded by StockNews.com to “Hold” Rating

by · The Cerbat Gem

StockNews.com upgraded shares of Accelerate Diagnostics (NASDAQ:AXDX – Free Report) from a sell rating to a hold rating in a research report sent to investors on Thursday morning.

Accelerate Diagnostics Price Performance

Shares of NASDAQ:AXDX opened at $1.85 on Thursday. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $5.78. The stock has a market capitalization of $46.32 million, a price-to-earnings ratio of -0.65 and a beta of 0.59. The company’s 50 day simple moving average is $1.78 and its 200 day simple moving average is $1.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned about 0.08% of Accelerate Diagnostics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 17.14% of the company’s stock.

About Accelerate Diagnostics

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories